Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis

Background: Epidermal growth factor receptor (EGFR) mutations are common in patients with non-small-cell lung cancer (NSCLC), particularly in Asian populations. Tyrosine kinase inhibitors (TKIs) are a first-line treatment in patients with mutant EGFR, but their use is often accompanied by drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xiaoyu, Guo, Xiaodan, Li, Ting, Hu, Wei, Zhang, Lin, Wu, Caisheng, Ye, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442341/
https://www.ncbi.nlm.nih.gov/pubmed/36071838
http://dx.doi.org/10.3389/fphar.2022.926890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442341/
https://www.ncbi.nlm.nih.gov/pubmed/36071838
http://dx.doi.org/10.3389/fphar.2022.926890

Ejemplares similares